Literature DB >> 16212815

Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: case study.

Christian Lotze1, Frank Schüler, William H Krüger, Carsten Hirt, Michael Kirsch, Silke Vogelgesang, Christian A Schmidt, Gottfried Dölken.   

Abstract

Relapse of peripheral non-Hodgkin's lymphoma (NHL) in the central nervous system commonly has a poor prognosis. Graft-versus-leukemia effects (GvL) contribute substantially to eradication of hematological malignancies after allogeneic stem cell transplantation. Few data are available describing GvL activity within the brain. We report the case of a man allografted for peripheral NHL. On day +83 after transplantation a CNS relapse of the lymphoma occurred. The brain was irradiated with 44 Gy, anti-CD20 antibodies were given, and the immunosuppression was withdrawn. Subsequently, limited-stage, chronic graft-versus-host disease occurred. The lymphoma regressed completely, and the patient has been in continuous complete remission for 30 months. The favorable course suggests substantial contribution of immunomodulation to excellent outcome.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16212815      PMCID： PMC1871735          DOI： 10.1215/S1152851705000256

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


  8 in total

Review 1.  Detection of minimal residual disease.

Authors:  G Dölken
Journal:  Adv Cancer Res       Date:  2001       Impact factor: 6.242

2.  Chimerism analysis on mononuclear cells in the CSF after allogeneic bone marrow transplantation.

Authors:  S Hibi; K Tsunamoto; S Todo; T Sawada; Y Ueda; M Taniwaki; M Naya; M Hojo; S Imashuku
Journal:  Bone Marrow Transplant       Date:  1997-09       Impact factor: 5.483

3.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.

Authors:  H J Kolb; J Mittermüller; C Clemm; E Holler; G Ledderose; G Brehm; M Heim; W Wilmanns
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

4.  Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma.

Authors:  G Varadi; R Or; J Kapelushnik; E Naparstek; A Nagler; C Brautbar; A Amar; M Kirschbaum; S Samuel; S Slavin; T Siegal
Journal:  Leuk Lymphoma       Date:  1999-06

5.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.

Authors:  R E Curtis; L B Travis; P A Rowlings; G Socié; D W Kingma; P M Banks; E S Jaffe; G E Sale; M M Horowitz; R P Witherspoon; D A Shriner; D J Weisdorf; H J Kolb; K M Sullivan; K A Sobocinski; R P Gale; R N Hoover; J F Fraumeni; H J Deeg
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

6.  Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.

Authors:  K van Besien; C S Ha; S Murphy; P McLaughlin; A Rodriguez; K Amin; A Forman; J Romaguera; F Hagemeister; A Younes; C Bachier; A Sarris; K S Sobocinski; J D Cox; F Cabanillas
Journal:  Blood       Date:  1998-02-15       Impact factor: 22.113

7.  Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.

Authors:  Jochen Casper; Wolfgang Knauf; Thomas Kiefer; Daniel Wolff; Beate Steiner; Ulrich Hammer; Rudolf Wegener; Hans-Dieter Kleine; Stefan Wilhelm; Agnes Knopp; Gernot Hartung; Gottfried Dölken; Mathias Freund
Journal:  Blood       Date:  2003-08-28       Impact factor: 22.113

8.  Long-term remission of APL with a second allogeneic BMT after CNS relapse following HLA-identical allogeneic BMT.

Authors:  C F Classen; K-M Debatin; W Friedrich; A S Schulz
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483
  8 in total
  3 in total

1.  Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.

Authors:  M Santisteban; Y Nieto; S De la Cruz; J Aristu; J L Zubieta; O Fernández Hidalgo
Journal:  Clin Transl Oncol       Date:  2007-07       Impact factor: 3.405

Review 2.  Secondary central nervous system lymphoma.

Authors:  Naoto Tomita; Fumio Kodama; Heiwa Kanamori; Shigeki Motomura; Yoshiaki Ishigatsubo
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

3.  Treatment of splenic marginal zone lymphoma of the CNS with high-dose therapy and allogeneic stem cell transplantation.

Authors:  Christoph Busemann; Andrej Gudzuhn; Carsten Hirt; Michael Kirsch; Silke Vogelgesang; Christian A Schmidt; Gottfried Dölken; William H Krüger
Journal:  Exp Hematol Oncol       Date:  2012-10-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.